Grants to Conquer the ‘Digital Divide’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

BETHESDA, Md-The National Cancer Institute has given four awards totaling $932,000 to four existing NCI contractors to develop research to understand, and pilot programs to breach, the “Digital Divide” that prevents many members of minorities from accessing cancer information on the Internet.

BETHESDA, Md—The National Cancer Institute has given four awards totaling $932,000 to four existing NCI contractors to develop research to understand, and pilot programs to breach, the “Digital Divide” that prevents many members of minorities from accessing cancer information on the Internet.

The four awards went to contractors who operate regional information centers for NCI’s Cancer Information Service (CIS). They will cover 1 year, with the possibility of a 6-month extension.

The awardees are the CIS New York State (Memorial Sloan-Kettering Cancer Center); CIS North Central and Mid-West Regions (University of Wisconsin, Madison, and Karmanos Cancer Center, Detroit); CIS New England Region (Yale Cancer Center); and CIS Mid-South Region (Markey Cancer Cener, Kentucky, and the Louisiana State University Health Sciences Center).

Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content